Arrowhead Pharmaceuticals says MHRA grants marketing authorisation for Redemplo for FCS in adults
ARWR•The MHRA granted marketing authorisation for Arrowhead Pharmaceuticals’ Redemplo (plozasiran) for adults with familial chylomicronaemia syndrome, and UK NICE recommended NHS funding for genetically confirmed FCS in adults.
1. UK authorisation and funding
Arrowhead Pharmaceuticals said the MHRA granted marketing authorisation for Redemplo (plozasiran) for adults with familial chylomicronaemia syndrome (FCS). NICE recommended NHS funding for genetically confirmed FCS in adults, and the treatment is a new option to reduce triglycerides for adults with FCS in England and Wales.
